imatinib mesylate has been researched along with Myelodysplastic Syndromes in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (76.60) | 29.6817 |
| 2010's | 9 (19.15) | 24.3611 |
| 2020's | 2 (4.26) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, B; Guan, J; Ma, J | 1 |
| Doi, S; Hamada, T; Kato, K; Kishimoto, W; Moriguchi, T; Tashiro, Y; Ueda, C; Yoshinaga, N | 1 |
| Ishikawa, T | 1 |
| Imataki, O | 1 |
| Chopra, A; Gogia, A; Jha, A; Kumar, R; Mallik, N | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Becker, H; Berg, T; Binder, M; Dierks, C; Duque-Afonso, J; Hackanson, B; Lairmore, MD; Lübbert, M; Martens, U; Mertelsmann, R; Schäfer, HS; Schnitzler, M; Zeiser, R | 1 |
| Einsele, H; Etschmann, B; Gattenlohner, S; Müller-Hermelink, HK; Völker, HU | 1 |
| Bendit, I; de Alencar Fischer Chamone, D; de Mello Conchon, MR; Dias, L; Dorlhiac-Llacer, PE; Ferreira, P; Kumeda, C; Lima, W | 1 |
| Altavilla, G; Arrigo, C; Pitini, V; Sauta, MG | 1 |
| Sadahira, Y; Takeuchi, M; Tsuchiyama, J; Yoshida, C | 1 |
| Gotlib, J; Pardanani, A; Tefferi, A | 1 |
| Bryan, J; Garcia-Manero, G; Issa, JP; Jabbour, E; Kantarjian, H; Prescott, H | 1 |
| Abe, T; Aizawa, Y; Furukawa, T; Karimata, K; Kozakai, T; Masuko, M; Moriyama, M; Shibasaki, Y; Toba, K; Ushiki, T; Yano, T | 1 |
| Dan, K; Hamada, Y; Nakamura, K; Tajika, K | 1 |
| Aessopos, A; Andreopoulos, G; Athanasiadou, A; Diamantopoulos, PT; Georgiou, G; Gratsias, N; Mantzourani, M; Meletis, J; Panagiotidis, P; Papakostas, E; Viniou, N | 1 |
| Hamilton, MS; Hunter, H; Kerr, JP; Tucker, D; Wickham, C | 1 |
| Al-Ali, HK; Bumm, T; Deininger, MW; Franke, C; Friedrich, T; Hennig, E; Krahl, R; Krohn, K; Leiblein, S; Müller, C; Niederwieser, D; Schmidt, E; Shepherd, P | 1 |
| Goldberg, SL; Hsu, JW; Madan, RA; Pecora, AL; Rowley, SD; Tantravahi, R | 1 |
| Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK | 1 |
| Drummond, MW; Holyoake, TL; Kaeda, J; Lush, CJ; Reid, FM; Vickers, MA | 1 |
| Chee, YL; Culligan, DJ; Holyoake, TL; Stevenson, D; Vickers, MA | 1 |
| Alo, G; Arrigo, C; Barresi, G; Pitini, V; Righi, M; Teti, D | 1 |
| Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Letvak, L; O'Brien, S; Rios, MB; Salvado, A; Talpaz, M; Thomas, D | 1 |
| Fukuhara, T; Maekawa, I; Miyake, T; Onozawa, M; Takahata, M; Yamamoto, Y | 1 |
| Blaise, D; Caillères, S; Lafage-Pochitaloff, M; Maurice, C; Mozziconacci, MJ; Sainty, D; Vey, N | 1 |
| Hoyer, J; Ketterling, RP; Mesa, RA; Steensma, DP | 1 |
| Alimena, G; Breccia, M; De Felice, L; Ferranti, G; Gallucci, C; Mancini, M; Mandelli, F | 1 |
| Berger, U; Hehlmann, R; Hochhaus, A; Lengfelder, E; Reiter, A | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S | 1 |
| Deininger, M; Loriaux, M | 1 |
| Klepfish, A; Patchenko, P; Rachmilewitz, EA; Rothman, R; Trakhtenbrot, L | 1 |
| Shannon, KM; Van Etten, RA | 1 |
| Giles, FJ; Jabbour, EJ | 1 |
| Abruzzo, LV; Cortes, J; Garcia-Manero, G; Kantarjian, H; Kovitz, C | 1 |
| Azhipa, O; Friedman, TM; Goldberg, SL; Hsu, JW; Korngold, R; Pecora, AL; Preti, RA; Rowley, SD; Tkachuk, Y; Zilberberg, J | 1 |
| Aulitzky, W; Cortes, J; Döhner, H; Fischer, T; Heidel, F; Huber, C; Kantarjian, H; Kindler, T; Letvak, L; Rücker, FG | 1 |
| Hoshino, T; Isoda, A; Mitsui, T; Nakahashi, H; Yoshida, Y | 1 |
| Apperley, JF; Chaidos, A; Kanfer, E | 1 |
| Cheung, K; Kamel-Reid, S; Lipton, JH; Ostro, D | 1 |
| Colomer, D; Espinet, B; Feliu, E; Granada, I; Grau, J; Juncà, J; Millá, F; Navarro, JT; Oriol, A; Ribera, JM | 1 |
| Baccarani, M; Cortes, J; Deininger, MW; Druker, BJ; Fischer, T; Gambacorti-Passerini, C; Gathmann, I; Goldman, JM; Guilhot, F; Hochhaus, A; Kantarjian, H; Niederwieser, D; Paquette, R; Park, B; Smith, D; So, C; Stone, R | 1 |
| Abdulhaq, H; Jalil, A; Lister, J; Makary, A; Rossetti, J; Shadduck, RK; Talreja, N | 1 |
| Corm, S; Deluche, L; Geffroy, S; Joha, S; Laï, JL; Nicolini, FE; Philippe, N; Preudhomme, C; Roche-Lestienne, C; Tigaud, I | 1 |
| Cortes, J; Kantarjian, H; Kebriaei, P; O'Brien, S; Ravandi, F; Thomas, D; Vega-Ruiz, A | 1 |
| Casadevall, N; Delmer, A; Legrand, O; Marie, JP; Rio, B; Ugo, V | 1 |
| Radich, JP | 1 |
14 review(s) available for imatinib mesylate and Myelodysplastic Syndromes
| Article | Year |
|---|---|
De nove Philadelphia chromosome-positive myelodysplastic syndromes with complex karyotype and p230
Topics: Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Philadelphia Chromosome | 2023 |
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.
Topics: Azacitidine; Benzamides; Decitabine; DNA Methylation; Humans; Imatinib Mesylate; Lenalidomide; Molecular Targeted Therapy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Thalidomide | 2014 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Causality; Decision Trees; Diagnosis, Differential; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Mastocytosis; mRNA Cleavage and Polyadenylation Factors; Mutation; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Platelet-Derived Growth Factor | 2010 |
Current and future management options for myelodysplastic syndromes.
Topics: Adenine Nucleotides; Anemia; Arabinonucleosides; Benzamides; Bone Marrow; Clofarabine; DNA Methylation; Drugs, Investigational; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Risk Factors; Thalidomide; Thrombopoietin | 2010 |
Translocation t(12;13)(p13;q14) in a patient with imatinib-sensitive MDS/MPD associated with resistance to treatment: review of the literature.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Translocation, Genetic | 2011 |
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2004 |
Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib.
Topics: Benzamides; Bone Marrow Transplantation; Chromosome Aberrations; Cohort Studies; Disease Progression; Hematopoiesis; Humans; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Myelodysplastic Syndromes; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2004 |
Focus on myeloproliferative diseases and myelodysplastic syndromes.
Topics: Anemia, Refractory; Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Models, Biological; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Pyrimidines; Signal Transduction | 2004 |
New agents in myelodysplastic syndromes.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Apoptosis; Arsenicals; Azacitidine; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytokines; DNA Methylation; Enzyme Inhibitors; Farnesyltranstransferase; Growth Substances; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Myelodysplastic Syndromes; Oligonucleotides, Antisense; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2005 |
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Risk Factors | 2006 |
Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
Topics: Acute Disease; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Assessment; Survival Analysis; Transplantation, Homologous | 2007 |
[Update on malignant hemopathies].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotoxins; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Lymphoma; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Tretinoin | 2002 |
The promise of gene expression analysis in hematopoetic malignancies.
Topics: Animals; Benzamides; DNA Fingerprinting; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines | 2002 |
1 trial(s) available for imatinib mesylate and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Stem Cell Factor; Survival Rate; Treatment Outcome | 2007 |
32 other study(ies) available for imatinib mesylate and Myelodysplastic Syndromes
| Article | Year |
|---|---|
[BCR-ABL1-positive myelodysplastic syndrome with neutropenia and anemia treated successfully with imatinib mesylate].
Topics: Aged, 80 and over; Anemia; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Myelodysplastic Syndromes; Neutropenia; Protein Kinase Inhibitors | 2020 |
A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Pancytopenia; Patient Selection; Phenotype; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2014 |
Development of myelodysplastic syndrome in a patient with chronic myelogenous leukemia treated with imatinib.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 7; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2015 |
XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors.
Topics: Adolescent; Adult; Age Factors; Aged; Animals; Benzamides; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myeloid, Acute; Medical Oncology; Mice; Middle Aged; Myelodysplastic Syndromes; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Transcription Factors | 2008 |
BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Topics: Aged; Benzamides; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Myelodysplastic Syndromes; Piperazines; Pyrimidines | 2009 |
Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.
Topics: Benzamides; Chromosomes, Human, Pair 7; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST.
Topics: Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Karyotyping; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines | 2009 |
Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.
Topics: Benzamides; Bone Marrow; Drug Resistance; Female; Humans; Imatinib Mesylate; Interferon-alpha; Mast Cells; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Point Mutation; Proto-Oncogene Proteins c-kit; Pyrimidines | 2009 |
Myelodysplastic syndrome with Ph negative monosomy 7 chromosome following transient bone marrow dysplasia during imatinib treatment for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 7; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines | 2011 |
[Loss of Philadelphia chromosome after graft failure following cord blood transplantation for Philadelphia chromosome-positive acute myeloid leukemia].
Topics: Benzamides; Fetal Blood; Graft Rejection; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Treatment Outcome | 2011 |
Lytic bone disease as the presenting feature of Philadelphia-positive monosomy 7 myelodysplasia progressing to acute myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Diseases; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Cytarabine; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pain; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Radiography; Vidarabine | 2012 |
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Blood Cells; Bone Marrow Cells; Clone Cells; Cohort Studies; Cytarabine; Dosage Compensation, Genetic; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Idarubicin; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Androgen; Remission Induction | 2003 |
Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.
Topics: Benzamides; Cell Lineage; Cell Transformation, Neoplastic; Clone Cells; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Myelodysplastic Syndromes; Piperazines; Pyrimidines | 2003 |
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine | 2003 |
Imatinib mesylate-induced molecular remission of Philadelphia chromosome-positive myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Imatinib Mesylate; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; RNA, Messenger; Transcription, Genetic | 2003 |
Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines | 2003 |
Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report.
Topics: Aged; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic | 2003 |
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recurrence | 2003 |
A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL.
Topics: Aged; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Drug Resistance, Neoplasm; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger; Translocation, Genetic | 2003 |
Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines | 2003 |
Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
Topics: Aged; Antineoplastic Agents; Benzamides; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Treatment Outcome | 2003 |
Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome.
Topics: Benzamides; Chromosomes, Human, Pair 8; Clone Cells; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Trisomy | 2004 |
[Chronic myeloproliferative diseases. Diagnosis and therapy].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Chronic Disease; Diagnosis, Differential; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Humans; Hydroxyurea; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins | 2003 |
Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML).
Topics: Benzamides; Chromosomes, Human, Pair 8; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Trisomy | 2004 |
Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.
Topics: Adult; Animals; Antilymphocyte Serum; Benzamides; Blast Crisis; Bone Marrow Transplantation; Cell Lineage; Combined Modality Therapy; Female; Gene Rearrangement, T-Lymphocyte; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Lymphocyte Depletion; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Rabbits; Remission Induction; T-Lymphocyte Subsets; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 3; Cytogenetic Analysis; Disease Progression; Fatal Outcome; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Recurrence; Treatment Failure | 2007 |
Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetics; Hematopoietic Stem Cells; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines | 2007 |
Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 7; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Treatment Outcome | 2007 |
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Chromosome Aberrations; Chronic Disease; Cytogenetic Analysis; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Logistic Models; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Piperazines; Prognosis; Pyrimidines; Thrombocytopenia; Treatment Failure; Treatment Outcome | 2007 |
Erythroid variant of chronic myelogenous leukemia.
Topics: Adult; Benzamides; Diagnosis, Differential; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Remission Induction; Thrombocytopenia | 2008 |
RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Chromosomes, Human; Chronic Disease; Core Binding Factor Alpha 2 Subunit; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Male; Middle Aged; Myelodysplastic Syndromes; Phenotype; Piperazines; Point Mutation; Pyrimidines; Retrospective Studies; Survival Rate; Transcription Factors; Translocation, Genetic; Trisomy | 2008 |
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome; Vincristine | 2008 |